(Q48093666)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446026%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446026%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author

Erik H van der Heijden

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446026%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

S F Mulder

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446026%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

M J Boers-Sonderen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446026%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

K C P Vissers

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446026%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

C J A Punt

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446026%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

C M L van Herpen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446026%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

21 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446026%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446026%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446026%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446026%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

331-338

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446026%20AND%20SRC:MED&resulttype=core&format=json

Pattern and prognostic factors in patients with malignant ascites: a retrospective study.

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0306-0

Malignant ascites: systematic review and guideline for treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0306-0

Vascular endothelial growth factor in pleural effusions of different origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0306-0

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0306-0

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0306-0

Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0306-0

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0306-0

An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0306-0

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0306-0

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0306-0

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0306-0

Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0306-0

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0306-0

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0306-0

Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0306-0

Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0306-0

A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites

21 January 2018

1 reference

12 December 2020

Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease

1 reference

12 December 2020

Malignant Pleural Effusion: Prognostic Factors for Survival and Response to Chemical Pleurodesis in a Series of 120 Cases

1 reference

12 December 2020

EORTC Receptor and Biomarker Study Group Report: a sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts

1 reference

12 December 2020

Recent advances in the diagnosis and management of malignant pleural effusions

1 reference

12 December 2020

Markedly elevated levels of vascular endothelial growth factor in malignant ascites

1 reference

12 December 2020

Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation

1 reference

12 December 2020

10.1007/S11523-014-0306-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446026%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference